Pharmacogenetics of osteoporosis

F1000 Biology Reports

Volumn 2, Issue 1, 2010, Pages

  Marini, Francesca ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MICRORNA; RALOXIFENE; RISEDRONIC ACID; VITAMIN D RECEPTOR;

AGING; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE TURNOVER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG TARGETING; FEMUR; FRACTURE; GENETIC POLYMORPHISM; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; OSTEOPENIA; OSTEOPOROSIS; PHARMACOGENETICS; RECEPTOR GENE; REVIEW; RISK; SPINE; TREATMENT RESPONSE;

EID: 78649350233     PISSN: 17404118     EISSN: 1757594X     Source Type: Journal    
DOI: 10.3410/B2-63     Document Type: Review

References (23)

1. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929-36.
2. Nguyen TV, Eisman JA: Pharmacogenomics of osteoporosis: opportunities and challenges. J Musculoskelet Neuronal Interact 2006, 6:62-72.
3. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K: Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008, 358:2355-65. (Pubitemid 351749159)
4. Jhonson JA, Evans WE: Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends Mol Med 2002, 8:300-5.
5. Weber WW: Effect of pharmacogenetics on medicine. Environ Mol Mutagen 2001, 37:179-184.
6. Manolopoulos VG: Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med 2007, 45:801-14.
7. Simsek M, Cetin Z, Bilgen T, Taskin O, Luleci G, Keser I: Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism. J Obstet Gynaecol Res 2008, 34:73-7. (Pubitemid 351143714)
8. Marini F, Falchetti A, Silvestri S, Bagger Y, Luzi E, Tanini A, Christiansen C, Brandi ML: Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin 2008, 24:2609-15.
9. Kruk M, Ralston SH, Albagha OM: LRP5 polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int 2009, 84:171-9.
10. Choi HJ, Choi JY, Cho SW, Kang D, Han KO, Kim SA, Kim SY, Chung YS, Shin CS: Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J 2010, 51:231-8.
11. Yahata T, Quan J, Tamura N, Nagata H, Kurabayashi T, Tanaka K: Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women. Hum Reprod 2005, 20:1860-6. (Pubitemid 40932369)
12. Rapuri PB, Gallagher JC, Knezetic JA, Haynatzka V: Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas 2006, 53:371-9.
13. Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P, Tung SS, Piaseu N, Chailurkit L, Chansirikarn S, Puavilai G, Rajatanavin R: Oestrogen-receptor- alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol (Oxf) 2000, 52:581-5. (Pubitemid 30337083)
14. Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH: The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women. J Bone Miner Res 2000, 15:2479-86.
15. Kurabayashi T, Tomita M, Matsushita H, Yahata T, Honda A, Takakuwa K, Tanaka K: Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol 1999, 180:1115-20. (Pubitemid 29259003)
16. Kurabayashi T, Matsushita H, Tomita M, Kato N, Kikuchi M, Nagata H, Honda A, Yahata T, Tanaka K: Association of vitamin D and estrogen receptor gene polymorphism with the effects of longterm hormone replacement therapy on bone mineral density. J Bone Miner Metab 2004, 22:241-7. (Pubitemid 38660955)
17. Giguère Y, Dodin S, Blanchet C, Morgan K, Rousseau F: The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J Bone Miner Res 2000, 15:1076-84.
18. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V: Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod 2003, 18:192-8.
19. Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR: Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren Fail 2005, 27:155-61.
20. Marc J, Prezelj J, Komel R, Kocijancic A: VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int 1999, 10:303-6.
21. Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F: BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 2005, 16:943-52.
22. Arko B, Prezelj J, Komel R, Kocijancic A, Marc J: No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2002, 81:147-52.
23. Qureshi AM, Herd RJ, Blake GM, Fogelman I, Ralston SH: COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int 2002, 70:158-63.